SCHEMBL3601899

SCHEMBL3601899

CC(C)(C)OC(=O)Nc1nc(C(=O)Cl)cs1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.45
PI4KB Q9UBF8 1/20 0.45
HDAC3 O15379 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC10 Q969S8 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
LCK P06239 5/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
ABCB1 P08183 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28334810 0.92 L3MBTL1 (0.43) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL10918388 0.89 PI4KB (0.42) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL10919161 0.87 HDAC3 (0.40) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL10919157 0.87 HDAC3 (0.40) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL4687185 0.87 L3MBTL1 (0.50) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL2213116 0.87 L3MBTL1 (0.62) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL17648650 0.85 L3MBTL1 (0.45) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL3382178 0.85 CYP1A2 (0.48) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL10915305 0.85 L3MBTL1 (0.43) L3MBTL1PI4KBHDAC3HDAC1HDAC2
SCHEMBL8983012 0.85 MAPT (0.51) L3MBTL1PI4KBHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS SPRING MILL PHARMA, INC. 2024-08-15 US disclosed
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
US-7799738-B2 Insecticidal 2-acylaminothiazole-4-carboxamides BAYER CROPSCIENCE AG (DE) 2010-09-21 US disclosed
US-7799738-B2 Insecticidal 2-acylaminothiazole-4-carboxamides BAYER CROPSCIENCE AG (DE) 2010-09-21 US disclosed
US-7799738-B2 Insecticidal 2-acylaminothiazole-4-carboxamides BAYER CROPSCIENCE AG (DE) 2010-09-21 US disclosed
CN-101351457-A Insecticidal 2-acylaminothiazole-4-carboxamides BAYER CROPSCIENCE AG (DE) 2009-01-21 CN disclosed
US-20080300136-A1 Insecticidal 2-Acylaminothiazole-4-Carboxamides BAYER CROPSCIENCE AG (DE) 2008-12-04 US disclosed
US-20080300136-A1 Insecticidal 2-Acylaminothiazole-4-Carboxamides BAYER CROPSCIENCE AG (DE) 2008-12-04 US disclosed
US-20080300136-A1 Insecticidal 2-Acylaminothiazole-4-Carboxamides BAYER CROPSCIENCE AG (DE) 2008-12-04 US disclosed
EP-1963290-A1 INSECTICIDAL 2 -ACYLAMINOTHIAZOLE-4 -CARBOXAMIDES Bayer CropScience Aktiengesellschaft (DE) 2008-09-03 EP disclosed
CN-101164618-A A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes METABASIS THERAPEUTICS INC (US) 2008-04-23 CN disclosed
CN-100352505-C Combination of FBP enzyme inhibitors and insulin sensitizers for the treatment of diabetes METABASIS THERAPEUTICS INC (US) 2007-12-05 CN disclosed
WO-2007051560-A1 INSECTICIDAL 2 -ACYLAMINOTHIAZOLE-4 -CARBOXAMIDES BAYER CROPSCIENCE AG (DE) 2007-05-10 WO disclosed
CN-1714866-A A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes METABASIS THERAPEUTICS INC (US) 2006-01-04 CN disclosed
CN-1350466-A Combination of FBP enzyme inhibitors and insulin sensitizers for the treatment of diabetes METABASIS THERAPEUTICS INC (US) 2002-05-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 L3MBTL1 637/4885PI4KB 1254/4885HDAC3 34/4885
US-20080300136-A1 Insecticidal 2-Acylaminothiazole-4-Carboxamides AADAC, HDHD5, HRH4 L3MBTL1 220/4885PI4KB 3567/4885HDAC3 33/4885
US-20240270762-A1 PENICILLIN-BINDING PROTEIN INHIBITORS PEPD, BPGM, EBPL L3MBTL1 455/4885PI4KB 1655/4885HDAC3 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.